THE BEST SIDE OF MOUNJARO

The demo attained both of those its Key endpoints, with semaglutide 2.4 mg demonstrating statistically major and top-quality advancements in liver fibrosis with no worsening of steatohepatitis, and resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH when compared to placebo.1For those who have any responses or would